Omadacycline for Acute Bacterial Skin and Skin Structure Infections

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Fredrick M AbrahamianPaul C McGovern

Abstract

Within the last decade, methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a frequent cause of purulent skin and soft tissue infections. New therapeutic options are being investigated for these infections. We report an integrated analysis of 2 randomized, controlled studies involving omadacycline, a novel aminomethylcycline, and linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Omadacycline in Acute Skin and Skin Structure Infections Study 1 (OASIS-1) initiated patients on intravenous omadacycline or linezolid, with the option to transition to an oral formulation after day 3. OASIS-2 was an oral-only study of omadacycline versus linezolid. In total, 691 patients received omadacycline and 689 patients received linezolid. Infection types included wound infection in 46.8% of patients, cellulitis/erysipelas in 30.5%, and major abscess in 22.7%. Pathogens were identified in 73.2% of patients. S. aureus was detected in 74.7% and MRSA in 32.4% of patients in whom a pathogen was identified. Omadacycline was noninferior to linezolid using the Food and Drug Administration primary endpoint of early clinical response (86.2% vs 83.9%; difference 2.3, 95% confidence interval -1.5 to 6....Continue Reading

References

Apr 1, 1985·Statistics in Medicine·O Miettinen, M Nurminen
Jan 9, 1998·Infectious Disease Clinics of North America·M C MarananR S Daum
Sep 2, 2009·Antimicrobial Agents and Chemotherapy·UNKNOWN International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC)
Oct 1, 2009·Emerging Infectious Diseases·John EdelsbergGerry Oster
Nov 26, 2011·Journal of Clinical Microbiology·Marcus J ZervosMyoung Kim
Jan 1, 1990·The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses·C F Carey, L Dall
Jul 5, 2012·JAMA : the Journal of the American Medical Association·Michael L LandrumClinton K Murray
Oct 17, 2012·Paediatric Respiratory Reviews·Sam Mehr, Nicholas Wood
Jul 19, 2013·Future Medicinal Chemistry·Kristin J Labby, Sylvie Garneau-Tsodikova
Dec 4, 2013·Antimicrobial Agents and Chemotherapy·A B MaconeS B Levy
Jun 29, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dennis L Stevens Infectious Diseases Society of America
Apr 17, 2016·Internal and Emergency Medicine·Marco FalconeFrancesco Violi
Jun 2, 2016·Expert Review of Clinical Pharmacology·Jaime E VerasteguiDavid P Nicolau
Jul 30, 2016·Bioorganic & Medicinal Chemistry·S Ken TanakaStephen Villano
Feb 15, 2018·Antimicrobial Agents and Chemotherapy·Laure StapertChris Pillar
Feb 7, 2019·The New England Journal of Medicine·William O'RiordanEvan Loh
Feb 7, 2019·The New England Journal of Medicine·Roman StetsEvan Loh

❮ Previous
Next ❯

Citations

Aug 2, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jason C Gallagher
Jan 24, 2020·Drugs·George G ZhanelJames A Karlowsky

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
scraping

Clinical Trials Mentioned

NCT02378480
NCT02877927

Software Mentioned

OASIS

Related Concepts

Related Feeds

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.